Foghorn Therapeutics Inc (FHTX) Directors and Executive Officers

Officers & Directors

Michael Mendelsohn
Director

Scott Biller
Director

B. Lynne Parshall
Director

Stephen DiPalma
Interim Chief Financial Officer (Principal Accounting and Financial Officer)

Douglas Cole
Director

Adrian Gottschalk
President, Chief Executive Officer and Director (Principal Executive Officer)

Simba Gill
Director

Adam Koppel
Director

Thomas Lynch Jr.
Director

Ian Smith
Director

Stephen DiPalma
Interim Chief Financial Officer (Principal Accounting and Financial Officer) ,

Foghorn Therapeutics Inc currently has 106 employees.

News about Foghorn Therapeutics Inc Key Personnel

“Foghorn Therapeutics: Navigating Challenges and Opportunities in Precision Oncology”

In an ever-evolving landscape of biopharmaceutical innovation, Foghorn Therapeutics Inc. stands at a critical juncture, showcasing both the promise and peril inherent in the quest for novel cancer treatments. The company recently provided an update on its clinical development programs, specifically relating to its candidate FHD-286, a treatment currently under investigation for patients with relapsed and/or refractory acute myeloid leukemia (AML). Clinical Development Insights:Foghorn announced that while objective clinical responses aligned with standard response criteria were observed in the Phase 1 dose escalation trial of FHD-286 in combination with decitabine, the results fell short of the efficacy thre...